This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at bakerdan@wsu.edu.
Advisory committee voted 6-4 against approval, plus one abstention, for use in acute coronary syndrome.
Tafamidis meglumine Vyndagel (Pfizer)
Advisory committee voted 13-4 that the presented study failed to demonstrate the drug slowed progression of familial amyloid polyneuropathy, but agreed (13-4) that it may improve lower limb function in some patients. 
